Evaluation of Pluripotent Stem Cell-Derived Blood Cells in Nonhuman Primate Model

非人灵长类动物模型中多能干细胞衍生血细胞的评估

• 批准号: 8579473
• 负责人: HANS-PETER KIEM
• 金额: $ 82.31万
• 依托单位: FRED HUTCHINSON CANCER RESEARCH CENTER
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-08-01 至 2017-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8579473
• 关键词: Address; Adverse effects; Affect; Allogenic; Autologous; Blood; Blood Cells; Blood Vessels; Bone Marrow; CD19 gene; CD20 Antigens; CD34 gene; Carmustine; Cells; Cellular biology; Clinical; Clonality; Coculture Techniques; Collaborations; Complication; Disease; Drug resistance; Endothelial Cells; Engineering; Engraftment; Epigenetic Process; Evaluation; Event; Excision; Gene-Modified; Generations; Generic Drugs; Genes; Genetic; Goals; Hematological Disease; Hematopoiesis; Hematopoietic; Hematopoietic stem cells; Hereditary Disease; Human; IGFBP2 gene; Immunodeficient Mouse; Life; Longevity; MGMT gene; MS4A1 gene; Macaca; Macaca nemestrina; Marrow; Mediating; Mediator of activation protein; Methods; Modeling; Modification; Monitor; Mus; Organ; PTPRC gene; Patients; Phenotype; Pluripotent Stem Cells; Population Heterogeneity; Pre-Clinical Model; Problem Solving; Production; Protocols documentation; Quality Control; Reagent; Relative (related person); Risk; Safety; Siblings; Signal Transduction; Source; Stem Cell Factor; Stem cell transplant; Stem cells; Technology; Testing; Therapeutic; Time; Translating; Translations; Transplantation; Umbilical cord structure; Undifferentiated; Vascular Endothelial Cell; Venous; base; chemotherapy; clinically relevant; cross reactivity; genetic element; genetic manipulation; graft vs host disease; improved; in vivo; induced pluripotent stem cell; nonhuman primate; notch protein; novel; novel strategies; pluripotency; public health relevance; receptor; reconstitution; residence; rituximab; stem; stem cell therapy; stemness; suicide gene; transgenic suicide gene

DESCRIPTION (provided by applicant): Allogeneic hematopoietic stem and progenitor cell (HSPC) transplantation has the potential to cure hematologic disease. However, many patients do not have an HLA matched donor, and graft-versus-host disease is a significant problem. Autologous patient HSPCs can be genetically corrected to cure the disease, but low yields of autologous HSPCs and ex vivo manipulation cause a loss of "stemness" leading to reduced engraftment. Thus, HSPC production from patient-specific induced pluripotent stem cells (iPSCs) would solve these problems and represent an unlimited cell source. To advance clinical translation of iPSC therapeutics, we propose a novel strategy to expand iPSC-derived HSPCs for hematopoietic transplantation. Specifically, we propose to engineer endothelial cells (ECs) for generation, expansion, and engraftment of putative HSPCs from pigtail macaque (Mn)iPSCs in the clinically relevant nonhuman primate model. In a promising collaboration with Dr. Shahin Rafii, we developed an effective, novel platform to expand macaque CD34+ LT- HSCs up to 25-fold by co-culture with Akt-activated human endothelial cells (E4+ECs). We recently found that iPSC-HSPCs expanded on E4+ECs have high levels of engraftment in NSG mice (up to 50% CD45+ cells). This evidence substantiates our novel approach to alter iPSC-HSPC biology through direct contact culture with angiocrine/hematopoietic signals unique to E4+ECs. The proposed studies will translate these findings to nonhuman primates and thus provide a major step toward producing iPSC-HSPCs with the capacity for hematopoietic reconstitution and correction of genetic diseases.

描述（由申请人提供）：异基因造血干细胞和祖细胞（HSPC）移植具有治愈血液病的潜力。然而，许多患者没有HLA匹配的供体，移植物抗宿主病是一个重要的问题。自体移植患者HSPC可以被遗传校正以治愈疾病，但是自体HSPC的低产量和离体操作导致“干性”的丧失，从而导致植入减少。因此，从患者特异性诱导多能干细胞（iPSC）生产HSPC将解决这些问题，并代表无限的细胞来源。为了推进iPSC疗法的临床转化，我们提出了一种新的策略来扩增iPSC衍生的HSPC用于造血移植。具体而言，我们提出在临床相关的非人灵长类动物模型中工程化内皮细胞（EC）以用于从猪尾猕猴（Mn）iPSC产生、扩增和植入推定的HSPC。在与Shahin Rafii博士的一次有希望的合作中，我们开发了一种有效的新型平台，通过与Akt激活的人内皮细胞（E4+ EC）共培养，将猕猴CD 34 + LT-HSC扩增至25倍。我们最近发现，在E4+ EC上扩增的iPSC-HSPC在NSG小鼠中具有高水平的植入（高达50%CD45+细胞）。该证据证实了我们通过与E4+ EC特有的血管分泌/造血信号直接接触培养来改变iPSC-HSPC生物学的新方法。拟议的研究将把这些发现转化为非人灵长类动物，从而为生产具有造血重建和纠正遗传疾病能力的iPSC-HSPC迈出了重要一步。